Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$62.34M+161.44%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Siddhartha C. Kadia
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 717
- Beta
- 1.08
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.43
Financials
Revenue
$62.34M+161.4%Net Income
$4.34M+33.5%EBITDA
$13.73M+108.6%Free Cash Flow
$3.71M+35.2%EPS (diluted)
$0.75-10.7%Shares Outstanding (diluted)
5.76M+48.9%Operating Expenses
$31.49MCash & Debt
$22.31MReturn of Capital
$898.0KRevenue by Segment (annual)
$249.13MDividend per Share
$0.16Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $249.13M | $6.71M | $1.22 |
| 2025 | $240.98M | $-1.97M | $-0.36 |
| 2024 | $216.19M | $-254.25M | $-47.20 |
| 2023 | $219.08M | $930.0K | $0.17 |
| 2022 | $184.34M | $1.87M | $0.36 |
| 2021 | $133.94M | $3.27M | $0.66 |
| 2020 | $117.69M | $1.78M | $0.32 |
| 2019 | $103.14M | $7.48M | $1.95 |
| 2018 | $96.18M | $-2.96M | $-0.79 |
| 2017 | $93.67M | $11.18M | $3.04 |
| 2016 | $84.66M | $11.17M | $3.10 |
| 2015 | $71.33M | $9.58M | $2.72 |
| 2014 | $52.72M | $9.00M | $2.61 |
| 2013 | $46.44M | $8.45M | $2.52 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MLAB's reported EPS growth of -5.4% a year over 13 years.
- EPS in 5 years
- $0.92
- Implied price
- $16.60
- Return from $134.09
- -34.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.25 — -93.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -15.4% | -45.7% | -43.2% | -41.1% | -39.3% | -37.6% |
| -10.4% | -42.5% | -39.9% | -37.6% | -35.7% | -33.9% |
| -5.4% | -39.3% | -36.5% | -34.2% | -32.1% | -30.3% |
| -0.4% | -36.1% | -33.2% | -30.7% | -28.5% | -26.6% |
| 4.6% | -32.9% | -29.8% | -27.2% | -24.9% | -22.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·12d ago·Positive
Mesa Laboratories, Inc. (MLAB) Q2 2027 Earnings Call Transcript Mesa Laboratories, Inc. (MLAB) Q2 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·13d ago·Neutral
What Mesa Laboratories (MLAB) Said on Its Q2 Earnings Call Mesa Laboratories NASDAQ: MLAB reported higher revenue and earnings for its fiscal 2027 second quarter and issued full-year guidance, while outlining plans to restructure its Clinical Genomics business and repurchase up to $40 million in shares.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
…ounces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance LAKEWOOD, Colo., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced results for its second fiscal quarter (“2Q27”) ended September 30, 2026, and issued full-year guidance for the first time (dollars in thousands, except per-share amounts).
View source ↗ - Newsglobenewswire.com·40d ago·Negative
…imately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced a savings plan (the “Savings Plan”) expected to reduce annualized operating costs by approximately $9.3 million.
View source ↗ - Newsgurufocus.com·81d ago·Neutral
Mesa Laboratories Inc (MLAB) Shares Surge 4.1% -- What GF Score of 75 Tells Investors On September 02, 2026, Mesa Laboratories Inc (MLAB) shares rose 4.1% to $130.65, reflecting a significant increase within a volatile 52-week range of $58.83 to
View source ↗ - Newsseekingalpha.com·104d ago·Positive
Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·104d ago·Negative
Mesa Laboratories Q1 Earnings Call Highlights Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.
View source ↗
Earnings
Wed, Feb 3(in 2 months)
Consensus estimate $3.02 per share
Typical surprise -5.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$1.80 vs $2.29miss
- Mon, Aug 10$2.68 vs $2.63beat
- Wed, May 27$2.76 vs $2.09beat
- Tue, Feb 3$3.07 vs $1.40beat
- Thu, Nov 6$1.76 vs $2.30miss
- Tue, Aug 5$2.32 vs $2.46miss
Estimates and results for MLAB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MLAB officers and directors.
- Bought
- $1.4m
- Sold
- $1.6m
5 trades
7 trades
- Sullivan John Jamessold
- Kadia Siddharthabought
- Tripeny R Tonybought
- Crennen Lyndsey Elizabethsold
- Archbold Brian Davidsold
- Sakys Johnsold
- Archbold Brian Davidsold
- Crennen Lyndsey Elizabethsold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MLAB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
